VCKD member, Dr. Volker Haase's findings published in Experimental Cell Research
July 21st 2017
Volker Haase, MD,
The Krick-Brooks Chair in Nephrology, Professor of Medicine, Cancer Biology, Molecular Physiology and Biophysics
Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies.Haase VH1.
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; Departments of Cancer Biology, and Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN, USA. Electronic address: firstname.lastname@example.org.
The oxygen-sensitive hypoxia-inducible factor (HIF) pathway plays a central role in the control of erythropoiesis and iron metabolism. The discovery of prolyl hydroxylase domain (PHD) proteins as key regulators of HIF activity has led to the development of inhibitory compounds that are now in phase 3 clinical development for the treatment of renal anemia, a condition that is commonly found in patients with advanced chronic kidney disease. This review provides a concise overview of clinical effects associated with pharmacologic PHD inhibition and was written in memory of Professor Lorenz Poellinger.
Copyright © 2017 Elsevier Inc. All rights reserved.
Anemia; Chronic kidney disease; Clinical trials; Hypoxia; Hypoxia-inducible factor; Oxygen; Prolyl hydroxylase domain
[Available on 2018-07-15]
Read full article here